Overview

A Study of GW685698X 100mcg Administered Once Daily Either in the Morning or the Evening and GW685698X 250mcg Administered Once Daily in the Evening Via DISKHALER for 28 Days in Subjects With Persistent Bronchial Asthma.

Status:
Completed

Trial end date:
2004-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the efficacy and safety of GW685698X 100mcg once daily either in the morning or the evening and GW685698X 250mcg administered once daily in the evening via DISKHALER for 28 days in subjects with persistent bronchial asthma.

Phase:

Phase 2

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Fluticasone
Xhance